Meeting
2018 ASCO Annual Meeting
Efficacy and safety of lurbinectedin (PM1183) in Ewing sarcoma: Final results from a phase 2 study.
Authors
Vivek Subbiah
The University of Texas MD Anderson Cancer Center, Houston, TX
Vivek Subbiah , Kamalesh Kumar Sankhala , Ravin Ratan , Enrique Sanz Garcia , Valentina Boni , Thierry Gil , Victor Manuel Villalobos , Sant P Chawla , Pilar Lardelli , Mariano Siguero , Carmen Maria Kahatt , Arturo Soto-Matos , Stefano Ferrari
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Bone Tumors
Clinical Trial Registration Number
NCT02454972
Citation
J Clin Oncol 36, 2018 (suppl; abstr 11519)
DOI
10.1200/JCO.2018.36.15_suppl.11519
Abstract #
11519
Poster Bd #
264
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Efficacy and safety of lurbinectedin (PM1183) in small cell lung cancer (SCLC): Results from a phase 2 study.
First Author: Jose Manuel Trigo Perez
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase II study of the safety and efficacy of discontinuing pegfilgrastim for pancreatic adenocarcinoma treated with FOLFIRINOX.
First Author: Masahiro Yanagi
Poster
2023 ASCO Annual Meeting
Phase II study of biweekly TAS-102, irinotecan and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO).
First Author: Patrick M Boland
Poster
2022 ASCO Annual Meeting
Efficacy and safety of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer: Preliminary results of a phase 1 study.
First Author: Ying Cheng